多替阿巴拉米片治疗艾滋病效果如何呢？

The ingredients of (Inbec) are dolutegravir 50mg + abacavir 0.6g + lamivudine 0.3g. Three drugs are used for the treatment of HIV-1 infection. It is the only three-in-one compound drug containing dolutegravir. Dolutegra abalamib tablets have been approved in more than 100 countries and recommended by many authoritative academic institutions in Europe and the United States as a first-line treatment for newly diagnosed AIDS patients. Comparing it with patients who failed the first-line regimen of the other two integrase inhibitors RAL (Ascent) and EVG (elvitegravir), doteabalamid (Inbec) has significantly fewer drug-resistant mutations than the other two drugs, making it less likely to develop drug resistance.

The recommended dosage of Inbec is one tablet, once daily. Adults or adolescents whose body weight is less than 40 kg should not be given dolutea as dolutea is a fixed-dose tablet and cannot be reduced. If the patient misses a dose of this product and there are more than 4 hours before the next dose, the patient should take this product as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule. This once-a-day, one-tablet medication method significantly reduces the medication burden of AIDS patients, thereby improving patients' medication compliance and significantly improving their quality of life.

Dr. Wim Swyzen, MD, head of medical affairs and vice president of GSK China/Hong Kong, said, "Through effective HIV drug treatment, the life spans of HIV patients and healthy people are getting closer and closer. Drug compliance and convenience of medication play an increasingly important role in further improving the quality of life of patients. Currently, there is no drug that can be taken once a day, one tablet at a time on the Chinese market. The approval of (Inbec) fills this gap and meets the urgent need for convenient medication use by doctors and patients."